Portal de Periódicos da CAPES

The future of red blood cell alloimmunization risk reduction

2015; Wiley; Volume: 55; Issue: 1 Linguagem: Inglês

10.1111/trf.12866

1537-2995

Seema Kacker, Paul M. Ness, R. Sue Shirey, William Savage, Karen E. King, Aaron A.R. Tobian,

Parvovirus B19 Infection Studies

TransfusionVolume 55, Issue 1 p. 222-224 LETTER TO THE EDITOR The future of red blood cell alloimmunization risk reduction Seema Kacker BS, Seema Kacker BS Department of Pathology, Johns Hopkins University, Baltimore, MDSearch for more papers by this authorPaul M. Ness MD, Paul M. Ness MD Department of Pathology, Johns Hopkins University, Baltimore, MDSearch for more papers by this authorR. Sue Shirey MS, MT(ASCP)SBB, R. Sue Shirey MS, MT(ASCP)SBB Department of Pathology, Johns Hopkins University, Baltimore, MDSearch for more papers by this authorWilliam J. Savage MD, PhD, William J. Savage MD, PhD Department of Pathology, Brigham and Women's Hospital, Boston, MASearch for more papers by this authorKaren E. King MD, Karen E. King MD Department of Pathology, Johns Hopkins University, Baltimore, MDSearch for more papers by this authorAaron A.R. Tobian MD, PhD, Aaron A.R. Tobian MD, PhD [email protected] Department of Pathology, Johns Hopkins University, Baltimore, MDSearch for more papers by this author Seema Kacker BS, Seema Kacker BS Department of Pathology, Johns Hopkins University, Baltimore, MDSearch for more papers by this authorPaul M. Ness MD, Paul M. Ness MD Department of Pathology, Johns Hopkins University, Baltimore, MDSearch for more papers by this authorR. Sue Shirey MS, MT(ASCP)SBB, R. Sue Shirey MS, MT(ASCP)SBB Department of Pathology, Johns Hopkins University, Baltimore, MDSearch for more papers by this authorWilliam J. Savage MD, PhD, William J. Savage MD, PhD Department of Pathology, Brigham and Women's Hospital, Boston, MASearch for more papers by this authorKaren E. King MD, Karen E. King MD Department of Pathology, Johns Hopkins University, Baltimore, MDSearch for more papers by this authorAaron A.R. Tobian MD, PhD, Aaron A.R. Tobian MD, PhD [email protected] Department of Pathology, Johns Hopkins University, Baltimore, MDSearch for more papers by this author First published: 13 January 2015 https://doi.org/10.1111/trf.12866Citations: 4Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Kacker S, Ness PM, Savage WJ, Frick KD, Shirey RS, King KE, Tobian AA. Cost-effectiveness of prospective red blood cell antigen matching to prevent alloimmunization among sickle cell patients. Transfusion 2014; 54: 86-97. 2Custer B, Hoch JS. Cost-effectiveness analysis: what it really means for transfusion medicine decision making. Transfus Med Rev 2009; 23: 1-12. 3Stubbs JR. Wrapping our arms around the cost of transfusion therapy. Transfusion 2014; 54: 259-262. 4 US Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. Evidence-Based Management of Sickle Cell Disease. Expert Panel Report 2014. Accessed online: http://www.nhlbi.nih.gov/guidelines. 2014. 5Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013; 122: 1062-1071. 6Vichinsky EP, Luban NL, Wright E, Olivieri N, Driscoll C, Pegelow CH, Adams RJ. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001; 41: 1086-1092. 7Shirey RS, Ness P. New concepts of delayed hemolytic transfusion reaction. In: S Nance, ed. Clinical and Basic Science of Immunohematology. Arlington, VA: AABB, 1991: 179-197. 8Taddie SJ, Barrasso C, Ness PM. A delayed transfusion reaction caused by anti-K6. Transfusion 1982; 22: 68-69. 9Kacker S, Ness PM, Savage WJ, Frick KD, Shirey RS, King KE, Tobian AA. Economic evaluation of a hypothetical screening assay for alloimmunization risk among transfused patients with sickle cell disease. Transfusion 2014. Citing Literature Volume55, Issue1January 2015Pages 222-224 ReferencesRelatedInformation